According to the news provider, Pfizer, the manufacturer of the medication, is facing a civil lawsuit that involves the complaints of at least 1,200 patients. Additionally, sales of the drug have been declining substantially, the news source said.
However, a number of experts claim that these issues could have been avoided if the trials, which tested the drug on thousands of smokers, had simply included people with depression.
While the practice may seem to benefit drug companies during beginning testing stages, the strategy can ultimately hurt them down the road when the treatment is marketed around the world, the news source said.
The FDA's decision to force Chantix to carry a "black box" warning and the subsequent lawsuits that have resulted reportedly followed complaints of erratic behaviors and a number of suicides associated with taking the medication, the news source said.